The medical cannabis industry is growing rapidly. However, there is a profound lack of knowledge and the appropriate clinical studies that demonstrate how to safely and effectively utilize cannabis for medical purposes.

Israel is at the forefront of medical marijuana research in the world led by Professor Raphael Mechoulam, an internationally recognized expert and pioneer in the field of cannabinoid-based medicine. He is renowned for his ground-breaking discoveries with over 50 years of experience.

In 1963, Mechoulam and his research partners revealed the structure of cannabidiol (CBD), a key ingredient in cannabis. By the following year, they had isolated THC for the first time, established its structure and synthesized it.

ESEV R&D, in collaboration with one of the leading clinical research organizations (CRO) in Israel, has launched a one-of-a-kind service for North American medical cannabis companies, to organize and oversee clinical trials, targeting specific medical conditions to demonstrate the efficacy of medical cannabis products.

ESEV’s experience and deep relationships within the Israeli medical community, puts the team in a unique position to implement clinical studies cost-effectively and in short timelines. 


Cannabidiol (CBD):

CBD is one of at least 85 active cannabinoids identified in cannabis. It is a major phytocannabinoid, accounting for up to 40% of the plant’s extract. CBD is considered to have a wider scope of medical applications than tetrahydrocannabinol (THC). Cannabinoid receptors are concentrated in certain areas of the brain associated with memory, pleasure, coordination and time perception.

TetraHydroCannabinol (THC):

THC is the chemical responsible for most of marijuana’s psychological effects. It acts much like the cannabinoid chemicals made naturally by the body, called endocannabinoids, also acting primarily through its affect on the cannabinoid receptors.